Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | GBA1 | P04062 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19779531 | 1.00 | FUCA1 (0.57) | FUCA1ALDH1A1GBA1DRD2DRD3 | |
| SCHEMBL19779526 | 1.00 | FUCA1 (0.57) | FUCA1ALDH1A1GBA1DRD2DRD3 | |
| SCHEMBL1335166 | 0.91 | FUCA1 (0.60) | FUCA1ALDH1A1GBA1DRD2DRD3 | |
| SCHEMBL16497869 | 0.91 | FUCA1 (0.60) | FUCA1ALDH1A1GBA1DRD2DRD3 | |
| SCHEMBL67177 | 0.91 | FUCA1 (0.60) | FUCA1ALDH1A1GBA1DRD2DRD3 | |
| SCHEMBL46428 | 0.91 | FUCA1 (0.60) | FUCA1ALDH1A1GBA1DRD2DRD3 | |
| SCHEMBL5939998 | 0.88 | ALDH1A1 (0.56) | FUCA1ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5939994 | 0.88 | ALDH1A1 (0.56) | FUCA1ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL694513 | 0.84 | FUCA1 (0.64) | FUCA1ALDH1A1GBA1DRD2DRD3 | |
| SCHEMBL30539363 | 0.84 | FUCA1 (0.64) | FUCA1ALDH1A1GBA1DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10906888-B2 | Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme | PFIZER INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20190315715-A1 | NOVEL PYRIMIDINE CARBOXAMIDES AS INHIBITORS OF VANIN-1 ENZYME | PFIZER INC. (US) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315715-A1 | NOVEL PYRIMIDINE CARBOXAMIDES AS INHIBITORS OF VANIN-1 ENZYME | VNN1, DPYD, MVD | FUCA1 658/4885ALDH1A1 416/4885GBA1 727/4885 |
| US-10906888-B2 | Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme | VNN1, DPYD, MVD | FUCA1 572/4885ALDH1A1 405/4885GBA1 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.